KCT0003577已完成未知
Phase I / II clinical trial of combination therapy with Doxorubicin and Durvalumab (MEDI4736) in patients with advanced soft tissue sarcoma
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Histologically confirmed soft tissue sarcoma.
- •2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •3. Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1
- •4. Body weight >30kg
- •5. Adequate normal organ and marrow function
- •6. Left ventricle ejection fraction = 45%
- •7. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.
- •8. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •9. Must have a life expectancy of at least 12 weeks
- •10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
排除标准
- •1. Histologically- or cytologically-confirmed Kaposi’s sarcoma or GIST
- •2. Previous treatment with anthracyclines
- •: patients received neoadjuvant/adjuvant doxorubicin can be enrolled into this study
- •3. Participation in another clinical study with an investigational product during the last 2 weeks
- •4. Receipt of the last dose of anticancer therapy 14 days prior to the first dose of study drug
- •5. Any previous treatment with a PD1 or PD-L1 inhibitor (including durvalumab) and/or PDGFR inhibitor
- •6. Mean QT interval corrected for heart rate (QTc) > 480 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s Correction
- •7. Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •8. Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment within 14 days prior to entering the study. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
- •9. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 14 days of the first dose of study drug
- •10. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
- •11. History of allogenic organ transplantation.
- •12. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).
- •13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris (within 6 months), cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse event or compromise the ability of the patient to give written informed consent
- •14. Known active infection
- •15. History of another primary malignancy.
- •16. History of leptomeningeal carcinomatosis who are neurologically unstable or have required active treatment.
- •17. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
- •18. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose.
- •19. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
研究者
相似试验
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
进行中（未招募）
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum